Taken together, these results support cMet as a driver of Plk1 inhibitor resistance in epithelial NSCLC in vivo, and the findings suggest that co‐inhibition of Plk1 and cMet increases apoptosis, leading to tumor regression in NSCLC. Here, PLK1 is linked to non-small cell lung carcinoma.